Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103850" target="_blank" >RIV/00843989:_____/13:E0103850 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1093/annonc/mdt371" target="_blank" >http://dx.doi.org/10.1093/annonc/mdt371</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/annonc/mdt371" target="_blank" >10.1093/annonc/mdt371</a>
Alternative languages
Result language
angličtina
Original language name
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
Original language description
Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC). An FORTIS-M trial was an international, multicenter, randomized, double-blind comparison of talactoferrin (1.5 g p.o. BID) versus placebo BID, in patients with stage IIIB/IV NSCLC whose disease had failed two or more prior regimens. Treatment was administered for a maximum of five 14-week cycles. The primary efficacy endpoint was overall survival (OS); secondary end points included 6- and 12-month survival, progression-free survival (PFS), and disease control rate (DCR). Seven hundred and forty-two patients were randomly assigned (2:1) to talactoferrin (497) or placebo(245). The median OS in the intent-to-treat (ITT) population was 7.66 months in the placebo arm and 7.49 months in the talactoferrin arm [hazard ratio (HR), 1.04; 95% CI, 0.873-1.24; P = 0.6602]. The 6-month survival rates were 59.9% (95%
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of oncology
ISSN
0923-7534
e-ISSN
—
Volume of the periodical
24
Issue of the periodical within the volume
n. 11
Country of publishing house
GB - UNITED KINGDOM
Number of pages
6
Pages from-to
"p. 2875-2880"
UT code for WoS article
000326643200029
EID of the result in the Scopus database
—